Investment Thesis
BridgeBio is a pre-revenue biotech company burning significant cash with minimal commercial traction and negative profitability across all metrics. While the company maintains strong liquidity with $373.7M in cash, the current burn rate of $113.9M annually suggests only ~3.3 years of runway, and there is no evidence of revenue generation capability or path to profitability.
Strengths
- Substantial cash reserves of $373.7M providing runway for operations
- Excellent liquidity position with 12.34x current ratio indicating no near-term solvency concerns
- Zero debt burden eliminating financial leverage risk
Risks
- Minimal revenue generation ($3.6K) indicating no meaningful commercial operations or product market fit
- Severe negative cash burn of -$113.9M annually with only ~3.3 years of cash runway remaining
- Persistent unprofitability with -$134.0M net loss and -145.8M operating loss showing no path to breakeven
- Negative free cash flow of -$114.5M indicating core business operations are not self-sustaining
- Deteriorating net loss on a year-over-year basis (-80.5% YoY) despite massive R&D spending
Key Metrics to Watch
- Monthly cash burn rate and projected runway duration
- Pipeline milestone achievements and clinical trial progression
- Revenue traction from any commercialized or soon-to-launch products
- Operating cash flow trajectory toward breakeven
- Form 4 insider activity patterns indicating confidence or concern
Financial Metrics
Revenue
3.6K
Net Income
-134.0M
EPS (Diluted)
$-4.30
Free Cash Flow
-114.5M
Total Assets
448.4M
Cash
373.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-4,046,032.2%
Net Margin
-3,719,311.9%
ROE
-32.6%
ROA
-29.9%
FCF Margin
-3,177,025.5%
Balance Sheet & Liquidity
Current Ratio
12.34x
Quick Ratio
12.34x
Debt/Equity
0.00x
Debt/Assets
8.3%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T17:54:13.292430 |
Data as of: 2025-12-31 |
Powered by Claude AI